AstraZeneca's PACIFIC Update Bolsters Imfinzi's Lead In Stage III Lung Cancer
Executive Summary
Full PACIFIC data show strong overall survival benefit in all comers, though not in a post hoc analysis of those with low PD-L1 expression, about 20% of the population.
You may also be interested in...
China Regulatory Roundup: AZ Gains PD-L1 Green Light Ahead Of Roche
Oncology continues to dominate new drug approvals in China as AstraZeneca gains the first clearance for a PD-L1 drug ahead of Roche. But there are as many as seven others in the class coming along, including from domestic firms Hengrui and CStone.
Regulatory Blessings Helping China CAR-Ts March Closer To Global Cancer Patients?
A regulatory framework that encourages physicians to conduct experimental cell and gene therapies have propelled China to become a major developer of such promising cancer-treating tools, but insiders say three are a plethora issues at stake.
AstraZeneca's Imfinzi Cements Market Position In Lung Cancer Segment With UK NICE Okay
But because of the remaining uncertainty in the clinical evidence for this "potentially curative treatment," – Imfinzi for Stage III NSCLC – UK reimbursement will come from the Cancer Drugs Fund until more data accrues from the PACIFIC study, due to report in 2021.